MNMD

Mind Medicine (MindMed) Inc. [MNMD] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MNMD Stock Summary

In the News

MNMD Financial details

Company Rating
-
Market Cap
681.74M
Income
-98.4M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-2.44
Forward P/E
-
PEG
-0.38
P/S
-
P/B
1.79
P/C
-
P/FCF
-4.47
Quick Ratio
3.78
Current Ratio
3.85
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.52
EPS next Y
-
EPS next Q
-
EPS this Y
59.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
31.11%
-
-
-
-
SMA20
15.79%
SMA50
29.41%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-58%
ROC
-0.8%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.41-12.22
52W High
+72.42%
52W Low
+934.5%
RSI
49
Rel Volume
0.14
Avg Volume
2.2M
Volume
298.41K
Perf Week
-10.36%
Perf Month
12.45%
Perf Quarter
-
Perf Half Y
71.27%
-
-
-
-
Beta
2.531
-
-
Volatility
0.94%, 1.74%
Prev Close
-5.44%
Price
20.69
Change
-0.43%

Something similar

Top by Market Cap
GOOGL
LLY.DE
ABEA.DE
AVGO
FXAIX
Same Sector
LFLYW
ALMDP.PA
MOLN.SW
HITC
JNJ.DE
Check Those
HURC
NBPU.L
JSWISPL.NS
300782.SZ
IS3U.DE
Similar Market Cap
EVT.TO
1290.HK
ACIO
2207.HK
3005.SR

Company Profile

Healthcare Biotechnology
  • Volume Average 2.2M
  • Market Capitalization 681.74M
  • Employee 57
  • CEO Mr. Robert Barrow
  • Headquarters Vancouver,BC,CA
  • IPO Date 2016-11-15
  • Website https://www.mindmed.co

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.